Zobrazeno 1 - 10
of 22
pro vyhledávání: '"Henoch S. Hong"'
Autor:
Alexandros Papachristofilou, Madeleine M. Hipp, Ute Klinkhardt, Martin Früh, Martin Sebastian, Christian Weiss, Miklos Pless, Richard Cathomas, Wolfgang Hilbe, Georg Pall, Thomas Wehler, Jürgen Alt, Helge Bischoff, Michael Geißler, Frank Griesinger, Karl-Josef Kallen, Mariola Fotin-Mleczek, Andreas Schröder, Birgit Scheel, Anke Muth, Tobias Seibel, Claudia Stosnach, Fatma Doener, Henoch S. Hong, Sven D. Koch, Ulrike Gnad-Vogt, Alfred Zippelius
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 7, Iss 1, Pp 1-14 (2019)
Abstract Background Preclinical studies demonstrate synergism between cancer immunotherapy and local radiation, enhancing anti-tumor effects and promoting immune responses. BI1361849 (CV9202) is an active cancer immunotherapeutic comprising protamine
Externí odkaz:
https://doaj.org/article/99e04455f1444be88b66a788433ed6e0
Autor:
Henoch S Hong, Fareed Ahmad, Johanna M Eberhard, Nupur Bhatnagar, Benjamin A Bollmann, Phillip Keudel, Matthias Ballmaier, Margot Zielinska-Skowronek, Reinhold E Schmidt, Dirk Meyer-Olson
Publikováno v:
PLoS ONE, Vol 7, Iss 9, p e44820 (2012)
NK cells are pivotal sentinels of the innate immune system and distinct subpopulations in peripheral blood have been described. A number of studies addressed HIV-induced alterations of NK cell phenotype and functionality mainly focusing on CD56(dim)C
Externí odkaz:
https://doaj.org/article/6596dd184b4947d28432e44552a7c71b
Autor:
Robin Liechti, Yervand Karapetyan, Stephanie Renaud-Tissot, Michelle Daniel, Sylvie Rusakiewicz, Nils Eling, Henoch S. Hong, Marie Morfouace, Bernd Bodenmiller, Jonas Windhager, Thomas Mrowiec, Daniel Schulz
Publikováno v:
Cancer Research. 81:2756-2756
Highly multiplexed imaging technologies are increasingly applied in biomedical research to identify underlying patterns of disease. As part of an IMI-funded project, the IMMUcan (Integrated immunoprofiling of large adaptive cancer patients cohorts) c
Autor:
Helge Bischoff, Claudia Stosnach, Wolfgang Hilbe, Alexandros Papachristofilou, Thomas Wehler, Miklos Pless, Sven D. Koch, Frank Griesinger, Tobias Seibel, Richard Cathomas, Georg Pall, Martin Früh, Ute Klinkhardt, Anke Muth, Ulrike Gnad-Vogt, Karl-Josef Kallen, Christian Weiss, Jürgen Alt, Birgit Scheel, Alfred Zippelius, Madeleine M. Hipp, Martin Sebastian, Mariola Fotin-Mleczek, Fatma Doener, Henoch S. Hong, Andreas Schröder, Michael Geißler
Publikováno v:
Journal for Immunotherapy of Cancer
Journal for ImmunoTherapy of Cancer, Vol 7, Iss 1, Pp 1-14 (2019)
Journal for ImmunoTherapy of Cancer, Vol 7, Iss 1, Pp 1-14 (2019)
Background Preclinical studies demonstrate synergism between cancer immunotherapy and local radiation, enhancing anti-tumor effects and promoting immune responses. BI1361849 (CV9202) is an active cancer immunotherapeutic comprising protamine-formulat
Autor:
Johanna M. Eberhard, P Keudel, Reinhold E. Schmidt, J Schulze zur Wiesch, Henoch S. Hong, Fareed Ahmad, Nupur Bhatnagar, Dirk Meyer-Olson
Publikováno v:
Clinical and Experimental Immunology. 186:227-238
Summary Immune senescence as well as disturbed CD8+ T cell differentiation are a hallmark of chronic HIV infection. Here, we investigated to what extent immune senescence is reversible after initiation of anti-retroviral treatment (ART). Peripheral b
Publikováno v:
Cancer Research. 80:1699-1699
The development of next generation therapeutics for cancer patients requires an improved understanding of the underlying mechanisms of resistance to existing therapies as well as novel biomarkers that can help identify patients most likely to benefit
Autor:
Marina Cella, Henoch S. Hong, Patrick L. Collins, R. Paul Johnson, Greer L. Gurewitz, Sofia I. Porter, Shasha Li, Eugene M. Oltz, Marco Colonna
Publikováno v:
Cell. 176(1-2)
Summary Natural killer (NK) cells develop from common progenitors but diverge into distinct subsets, which differ in cytokine production, cytotoxicity, homing, and memory traits. Given their promise in adoptive cell therapies for cancer, a deeper und
Autor:
Ingmar Hoerr, Alexander Knuth, Alfred Zippelius, Tanja Strack, Jochen Probst, Ulrike Gnad-Vogt, Florian Von Der Muelbe, Djordje Atanackovic, Andreas Gröschel, Frank Mayer, Michael Thomas, Volker Wiegand, Henoch S. Hong, Anke Muth, Andreas Schröder, Lotta von Boehmer, Folker Schneller, Karl-Josef Kallen, Martin Sebastian, Thomas Lander, Jan Stöhlmacher, Birgit Scheel, Martin Reck, Sven D. Koch, Mariola Fotin-Mleczek, Helga Bernhard
Publikováno v:
Cancer immunology, immunotherapy : CII. 68(5)
CV9201 is an RNActive®-based cancer immunotherapy encoding five non-small cell lung cancer-antigens: New York esophageal squamous cell carcinoma-1, melanoma antigen family C1/C2, survivin, and trophoblast glycoprotein. In a phase I/IIa dose-escalati
Autor:
Dirk Meyer-Olson, Roland Jacobs, Nupur Bhatnagar, Reinhold E. Schmidt, I-Na Lu, Fareed Ahmad, Matthias Ballmaier, Henoch S. Hong, Johanna M Eberhard
Publikováno v:
European Journal of Immunology. 44:3368-3379
Monocytes are known to engage in reciprocal crosstalk with NK cells but their influence on NK-cell-associated antibody-dependent cellular cytotoxicity (ADCC) is not well understood. We demonstrate that in humans FcγRIII (CD16)-dependent ADCC by NK c
Autor:
Henoch S. Hong, Volker Wiegand, James M. Billingsley, Andreas Schröder, Birgit Scheel, Ulrike Gnad-Vogt, Sven D. Koch, Ingmar Hoerr, Karl-Josef Kallen, Linus Backert, Mariola Fotin-Mleczek, Oliver Kohlbacher
Publikováno v:
Oncoimmunology
We recently completed a phase I/IIa trial of RNActive® CV9201, a novel mRNA-based therapeutic vaccine targeting five tumor-associated antigens in non-small cell lung cancer (NSCLC) patients. The aim of the study presented here was to comprehensively